INCOME TAXES	3 Months Ended
Mar. 31, 2013
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three months ended March 31, 2013 and 2012, the effective tax rate (“ETR”) was 25.7% and 27.5%, respectively. The lower ETR was primarily attributable to management’s assertion that certain current year foreign earnings and profits are permanently invested abroad. The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of March 31, 2013 and December 31, 2012, was $85.1 million and $75.9 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions. Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.3 million as of March 31, 2013.

INCOME TAXES

3 Months Ended

Mar. 31, 2013

For the three months ended March 31, 2013 and 2012, the effective tax rate (“ETR”) was 25.7% and 27.5%, respectively. The lower ETR was primarily attributable to management’s assertion that certain current year foreign earnings and profits are permanently invested abroad.

The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of March 31, 2013 and December 31, 2012, was $85.1 million and $75.9 million, respectively. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (“BMS”), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.3 million as of March 31, 2013.